|
1.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigacio Biomedica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, J.Y. (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 -  10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
2.
|
|
12 p, 804.5 KB |
RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT
/
Baron, Frédéric (University of Liege) ;
Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ;
Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Milpied, Noel (University of Bordeaux) ;
Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ;
Bacigalupo, Andrea (Ospedale San Martino) ;
Blaise, Didier (Aix-Marseille Université) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Socié, Gérard (Hospital Saint-Louis) ;
Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ;
Schmid, Christoph (University of Munich) ;
Giebel, Sebastian (Gliwice Branch) ;
Gorin, Norbert-Claude (Hospital Saint Antoine) ;
Esteve, Jordi (Hematology. Hospital Clinic) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Mohty, Mohamad (UMRs 938) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Nagler, Arnon (The Chaim Sheba Medical Center) ;
Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038
|
|
|
3.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
4.
|
|
9 p, 406.9 KB |
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
/
Saad, Ayman (The Ohio State University) ;
Lamb, Lawrence (University of Alabama at Birmingham) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Spellman, Stephen (National Marrow Donor Program/Be the Match) ;
Couriel, Daniel R (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin (Anderson Cancer Center) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Agrawal, Vaibhav (Indiana University School of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Beitinjaneh, Amer (University of Miami) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Buchbinder, David Kyle (Children's Hospital of Orange County) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Cairo, Mitchell S. (New York Medical College) ;
Castillo, Paul A. (UF Health Shands Children's Hospital) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Diaz, Miguel Angel (Hospital Infantil Universitario Nino Jesus) ;
Farhan, Shatha (Henry Ford Hospital Bone Marrow Transplant Program) ;
Floisand, Yngvar (The National Hospital) ;
Frangoul, Haydar A. (Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute) ;
Gadalla, Shahinaz M. (National Cancer Institute) ;
Gajewski, James (Consultant at Lu Daopei Hospital) ;
Gale, Robert Peter (Imperial College London) ;
Gandhi, Manish (Mayo Clinic) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute) ;
Hematti, Peiman (University of Wisconsin Hospital and Clinics) ;
Hildebrandt, Gerhard C. (University of Kentucky) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Khandelwal, Pooja (Cincinnati Children's Hospital Medical Center) ;
Lazaryn, Aleksandr (H. Lee Moffitt Cancer Center) ;
MacMillan, Margaret (University of Minnesota Blood and Marrow Transplant Program) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Mehta, Parinda A. (Cincinnati Children's Hospital Medical Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center) ;
Olsson, Richard (Uppsala University) ;
Patel, Sagar (Cleveland Clinic Foundation) ;
Qayed, Muna (Emory University School of Medicine) ;
Rangarajan, Hemalatha G. (Nationwide Children's Hospital) ;
Reshef, R. (Columbia University Medical Center) ;
Ringden, O. (Karolinska Institutet (Estocolm, Suècia)) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Schouten, H.C. (Academische Ziekenhuis) ;
Schultz, K.R. (The University of British Columbia) ;
Seo, S. (Dokkyo Medical University) ;
Shaffer, B.C. (Memorial Sloan Kettering Cancer Center) ;
Solh, M. (Northside Hospital) ;
Teshima, T. (Hokkaido University Hospital) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Verdonck, L.F. (Isala Clinic) ;
Vij, R. (Washington University School of Medicine) ;
Waller, E.K. (Emory University) ;
William, B. (The Ohio State University) ;
Wirk, B. (Seattle Cancer Care Alliance) ;
Yared, J.A. (University of Maryland) ;
Yu, L.C. (Children's Hospital/Louisiana State University Medical Center) ;
Arora, M. (University of Minnesota Medical Center) ;
Hashmi, S. (Mayo Clinic) ;
Universitat Autònoma de Barcelona
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). [...]
2019 - 10.1016/j.bbmt.2019.05.007
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1875-1883
|
|
|
5.
|
|
10 p, 680.7 KB |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
/
Ahmed, Sairah (University of Texas) ;
Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Litovich, Carlos Alejandro (Medical College of Wisconsin) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ;
Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ;
Cohen, Jonathon B. (Emory University School of Medicine) ;
Farooq, Umar (University of Iowa Hospitals and Clinics) ;
Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ;
Herrera, Alex F. (City of Hope National Medical Center) ;
Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ;
Inwards, David (Mayo Clinic) ;
Kanate, Abraham Sebastian (West Virginia University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Munshi, Pashna (Georgetown University Hospital) ;
Murthy, Hemant S. (University Florida College of Medicine) ;
Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ;
Nieto, Yago (University of Texas) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ;
Yared, Jean A. (University of Maryland) ;
Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ;
Fenske, Timothy S. (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868
|
|
|
6.
|
|
20 p, 1.9 MB |
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
/
Menghrajani, Kamal (Leukemia Service) ;
Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center) ;
Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Assal, Amer (Columbia University Irving Medical Center) ;
Bacher, Vera Ulrike (Bern University Hospital) ;
Badawy, Sherif M. (Northwestern University Feinberg School of Medicine) ;
Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Bredeson, Christopher (Ottawa Hospital Research Institute) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Castillo, Paul (UF Health Shands Children's Hospital) ;
Cerny, Jan (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center) ;
DeFilipp, Zachariah (Massachusetts General Hospital) ;
Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine) ;
Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH)) ;
Gale, Robert Peter (Haematology Research Centre. Department of Immunology and Inflammation. Imperial College London) ;
Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System) ;
Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital) ;
Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ;
Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center) ;
Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky) ;
Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH) ;
Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program) ;
Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute) ;
Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine) ;
Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University) ;
Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre) ;
Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center) ;
Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center) ;
Olsson, Richard (Centre for Clinical Research Sormland. Uppsala University) ;
Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center) ;
Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University) ;
Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center) ;
Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center) ;
Seo, Sachiko (Department of Hematology and Oncology. Dokkyo Medical University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital) ;
Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center) ;
Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic) ;
Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH) ;
Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center) ;
Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester) ;
Kebriaei, Partow (Department of Stem Cell Transplantation. Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center) ;
Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota) ;
Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. [...]
2022 - 10.1182/bloodadvances.2021004881
Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847
|
|
|
7.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Jacobsohn, David A. (Children's National Medical Center) ;
Jain, Tania (Johns Hopkins University School of Medicine) ;
Johnston, Laura (Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Duke University School of Medicine) ;
Liu, Hien (Moffitt Cancer Center) ;
MacMillan, Margaret L (University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (University of Kansas Cancer Center) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Oregon Health & Science University) ;
Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Washington University School of Medicine) ;
Riches, Marcie L. (University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Wake Forest University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
8.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
|
9.
|
|
13 p, 1.0 MB |
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT
/
Sanz, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Galimard, J. E. (EBMT Paris Office. Hospital Saint Antoine) ;
Labopin, Myriam (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ;
Angelucci, Emanuele (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ;
Ciceri, Fabio (Haematology and BMT) ;
Blaise, Didier (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ;
Cornelissen, J. J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ;
Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ;
Diez-Martin, J. L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ;
Savani, B. N. (Vanderbilt University Medical Center) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Nagler, Arnon (ALWP of the EBMT Office. Saint Antoine Hospital) ;
Mohty, Mohamad (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46
|
|
|
10.
|
|
11 p, 572.5 KB |
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
/
Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Abecasis, Manuel (Instituto Portugues de Oncologia) ;
Aerts, E. (University Hospital Zurich (Suïssa)) ;
Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ;
Arat, Mutlu (HSCT Unit. Sisli Florence Nightingale Hospital) ;
Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ;
Baron, Frederic (CHU and University of Liege) ;
Basak, G. (Medical University of Warsaw) ;
Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ;
Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ;
Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ;
Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ;
Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ;
Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ;
Fukuda, T. (HSCT Division. National Cancer Center Hospital) ;
Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ;
Kuball, J. (Department of Haematology. University Medical Centre) ;
Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ;
Lazarus, H. (Case Western Reserve University) ;
Masszi, T. (St László Hospital (Hongria)) ;
Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ;
Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ;
NiChonghaile, M. (Trinity College Dublin) ;
Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ;
Pagliuca, A. (King's College Hospital NHS Foundation Trust) ;
Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ;
Petersen, F. B. (LDS Hospital) ;
Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ;
Ruutu, T. (Helsinki University Hospital (Finlàndia)) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ;
Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ;
Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ;
Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ;
Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ;
Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ;
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
